Analysis: FDA Approving More Drugs (Bio-IT World)
November 30, 2006 | "The pharmaceutical industry must really enjoy the change in seasons because October proved to be the most robust month of the year, with 15 new drug application (NDA) approvals and five new molecular entity (NMEs) approvals," James Kumpel, an analyst with Friedman, Billings & Ramsey, stated in a report issued Tuesday.

Abraxis receives FDA approval for Ampicillin, Sulbactam injection (PharmaBiz)
Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the combination drug Ampicillin and Sulbactam for Injection, 15g, USP, the generic equivalent of Pfizer Inc.'s Unasyn.